Breast Lift in NZ
Breast Lift in NZ section, includes general infrmation about Breast Lift Procedure, Breast Lift NZ Local News, Breast Lift NZ Surgeon Locator and other Breast Lift related material.
Breast Lift Procedure
A mastopexy or breast lift is a surgical procedure performed to reshape the breast and return it to a more youthful position. Drooping of the breast may occur after pregnancy as well as aging. Frequently a breast implant may be used in conjunction with a breast lift in order to achieve better results. Depending on the amount of breast lifting that needs to be accomplished, different techniques may be used that involve different incisions. Generally, the more lifting that is required, the larger the incision (and therefore the scar).
Other Breast Lift Procedures
All Breast Procedures
Breast Lift NZ (current)
NZ Breast Reduction
NZ Breast Implants
NZ Implant Removal
NZ Armpit Incision
More NZ info...
New Zealand Regions New Zealand consists of two main islands and a number of smaller ones.
North Island – Warm, with scenery ranging from sandy beaches, through rolling farmland and forests to active volcanic peaks.
South Island – Spectacular mountainss and fiords, large beech forests, beautiful beaches.
Stewart Island – heavily forested, a wilderness paradise for trampers with wonderful bird song. Only place to a see a sun-bathing (feathered) kiwi on Masons Beach!
Chatham Islands
Sub-Antarctic Islands – Very difficult to get to unless you're on a scientific expedition or deep sea fishing vessel
New Zealand Visas and documentation All visitors who are not citizens of New Zealand need a passport to enter. Australian passport holders may enter New Zealand without a visa and stay as long as they wish without restrictions (including on employment). British passport holders can be granted a visa-free Visitor's Permit for up to six months on arrival. Citizens of a large number of other countries can be granted a visa-free visitor's entry for up to three months on arrival, check the list of Visa Free Countries. All these waivers, including the one for Australians, can be refused. In particular, potential visitors with criminal records or who have been refused entry to or deported from any country should check with New Zealand immigration about whether they need to apply for a visa.
Visitors from countries not in the visa-free list or those wishing to stay longer than the maximum visa-free period for their nationality, will need to apply for an appropriate visa. Check the Immigration New Zealand web page for details.
Plastic Surgery News...
- Psoriasis patients across the UK are experiencing differing and sometimes sub-standard levels of care, according to a new survey by the British Association of Dermatologists and Royal College of Physicians. Dr Colin Holden, President of the British Association of Dermatologists said: "Psoriasis is a chronic inflammatory skin disease which can have a huge physical and psychological impact, and as such patients require a high standard of care.
- A study published early online in Thorax has explored the relationship between montelukast and the onset of Churg-Strauss syndrome (CSS), a rare small-vessel vasculitis that is potentially life-threatening. This follows concerns that this condition might be precipitated by the drug.
Researchers retraced the medication histories of 78 CSS patients from France and Germany and compared exposures to montelukast and other asthma medications during the 3-month 'index' period immediately preceding CSS onset with those of 4 previous 3-month 'control' periods. The odds ratio (OR + 95% CI) for CSS onset were as follows:
• 4.5 (1.5 to 13.9) for montelukast
• 3.0 (0.8 to 10.5) for inhaled long-acting beta2-agonists
• 1.7 (0.5 to 5.4) for inhaled corticosteroids
• 4.0 (1.3 to 12.5) for oral corticosteroids
Montelukast exposure during control periods increased over 3 consecutive calendar periods of CSS onset from 1999 to 2003 (p for trend = <0.0001).
The researchers note from these findings that though montelukast was associated with over a 4 fold higher risk of CSS onset within 3 months, the estimates obtained for the other asthma medicines (though only statistically significant for oral corticosteroids) examined suggest that “this link is confounded by a general escalation of asthma therapy before CSS onset” and the montelukast-CSS association observed is also likely to be explained by its increasing use over time.” They conclude “taken together, these findings might suggest that the association with CSS onset is not specific to montelukast but a phenomenon possibly associated with the group of medications prescribed for long-term control of severe asthma.”